Drug | Indication | Agents | Pts | ORR (%) | OS | PFS | DOR | TRAEs | NCT | References |
---|---|---|---|---|---|---|---|---|---|---|
EV | la/mUC | EV + Pembro | 76 | 64.5 | – | – | – | Skin reactions, peripheral neuropathy | NCT03288545 | [1] |
EV | 73 | 45.2 | – | – | – | |||||
NMIBC | EV | Trials in progress | NCT05014139 | [2] | ||||||
SG | la/mUC | Cohort 1 SG | 113 | 28 | 10.9 | 5.4 | 6.1 | Neutropenia, anemia, | NCT03547973 | [3] |
Cohort 2 SG | 38 | 32 | 13.5 | 5.6 | 5.6 | Leukopenia, fatigue | [4] | |||
Cohort 3 SG + Pembro | 41 | 41 | 12.7 | 5.3 | 11.1 | Diarrhea, febrile | [5] | |||
Cohort 5 SG + ZIM versus ZIM versus avelumab | Trials in progress | Neutropenia | [6] | |||||||
Cohort 6 SG versus SG + CPI versus carboplatin/GEM | Trials in progress | [7] | ||||||||
mUC | SG + IPI + NIVO | 6 | 66.6 | – | 8.8 | 9.2 | Anemia, neutropenia, Pruritus, fatigue, Diarrhea, lymphopenia, arthralgia | NCT04863885 | [8] | |
RC48 | HER2 + laUC/mUC | Trials in progress | NCT04879329 | [10] |